Indiana University researchers have discovered that blocking the IDOL enzyme in neurons doesn't just clear toxic Alzheimer's plaques—it also lowers genetic risk (APOE4) and builds cognitive resilience. Read on to learn how this discovery could pave the way for a revolutionary new pill.

The FDA has cleared the Elecsys pTau217 blood test for Alzheimer's. Discover how this single-biomarker assay boosts primary care diagnostic accuracy from 65% to 93%.

Discover how the new p-tau217 blood test and the LEQEMBI IQLIK® autoinjector are revolutionizing Alzheimer's diagnosis and treatment at home.

Learn about the true economic and social impact of Alzheimer's, the burden on unpaid caregivers, and why diversity in medical research is key to a cure.

Explore how tau-targeting drug Diranersen and a newly diversified research pipeline are reshaping Alzheimer's treatment and slowing cognitive decline.

Discover how modern neurology is moving beyond amyloid to tackle atypical Alzheimer’s variants, neuroinflammation, and systemic factors for personalized care.

Discover why new Alzheimer's antibody treatments like lecanemab aren't enough on their own and why daily habits like exercise and diet play a critical role in brain health.

A study published in the American Journal of Epidemiology (August 2026) addressed this question. Researchers tracked cognitively healthy older adults over a 21-year period to evaluate how consistent, sustained fish consumption influences the long-term risk of developing Alzheimer's disease.

We often think of the heart and the brain as two separate systems—the pump and the computer. However, a groundbreaking study from Vanderbilt University Medical Center, recently highlighted in the journal Alzheimer's & Dementia, suggests that these two organs are more closely linked than we ever imagined.

For decades, we’ve treated Alzheimer’s like a collapsing building. We usually don’t call the engineers until the roof is already caving in—when memory loss is so severe that it disrupts daily life. The medical criteria from 1984, which set the standard for diagnosis for a long time, were built on this "end-stage" philosophy. By the time we diagnosed the disease, the damage was often irreparable.

For decades, the world of medical research has faced a quiet but massive problem: most clinical trials don't look like the real world. While science moves faster than ever, the way we find people to participate in life-saving studies is stuck in the past. This is especially true for underrepresented communities—including Black, Hispanic, and Asian Americans

For decades, the search for an Alzheimer's cure focused almost entirely on one thing: clearing out a protein called amyloid that builds up in the brain. But as we move through 2026, the landscape of medical research is undergoing a massive and hopeful transformation.

When you or someone you love starts becoming a bit forgetful or feels like they are in a "fog," it is natural for your mind to jump to the scariest conclusion: Alzheimer's. That anxiety can be overwhelming, making every misplaced set of keys or forgotten name feel like a major warning sign.

Historically, scaling a clinical tool meant navigating a fragmented landscape where building a solution for one hospital required rewriting the code entirely for the next. This "bespoke barrier" has long been the primary bottleneck in scaling precision neurology.

If your clinical trial recruitment strategy still relies on cold-calling lists of "eligible" patients scraped from five-year-old EHR data, you aren’t just behind the times—you’re actively sabotaging your own FDA compliance.

Focus: Translating clinical trial data into real-world medicine, and how AI can bridge the gap between expensive PET scans and scalable blood tests.

Focus: Highlighting massive recent 2026 AI milestones in neurodegeneration and the translation of raw science into software tools.

The biggest breakthrough shaking up the medical community is the arrival of ultra-precise blood-based biomarkers (like the pTau217 test). Scientists can now detect microscopic traces of Alzheimer’s proteins floating right in your bloodstream.

Enter the U.S. POINTER Trial, a massive, multiyear clinical study designed to answer one definitive question: Can structured lifestyle changes protect our brains as we age? The results are in, and they are the ultimate dose of medical empowerment.

Alzheimer’s disease is one of the most frustratingly difficult and heartbreaking medical conditions of our modern era. Right now, it is a disease that affects more than 50 million people all around the world